- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.70 Å
- Oligo State
- hetero-2-2-2-2-2-2-mer
- Ligands
- 2 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 30 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
EDO.3: 6 residues within 4Å:- Chain A: Y.159, E.162, P.163, V.164, P.181, A.182
Ligand excluded by PLIPEDO.4: 6 residues within 4Å:- Chain A: L.155, V.183, S.191, L.192, S.193
- Chain B: T.178
Ligand excluded by PLIPEDO.8: 5 residues within 4Å:- Chain B: Q.38, R.46, I.59, P.60, F.63
Ligand excluded by PLIPEDO.9: 5 residues within 4Å:- Chain B: L.11, L.13, R.18, A.19, T.20
Ligand excluded by PLIPEDO.10: 4 residues within 4Å:- Chain B: A.144, K.145, V.146, E.161
Ligand excluded by PLIPEDO.11: 4 residues within 4Å:- Chain B: P.141, E.143, Q.199
- Ligands: EDO.12
Ligand excluded by PLIPEDO.12: 4 residues within 4Å:- Chain B: S.12, E.105, E.143
- Ligands: EDO.11
Ligand excluded by PLIPEDO.13: 6 residues within 4Å:- Chain B: P.119, Y.186, N.210, R.211, G.212, E.213
Ligand excluded by PLIPEDO.14: 6 residues within 4Å:- Chain C: Y.159, E.162, P.163, V.164, P.181, A.182
Ligand excluded by PLIPEDO.17: 4 residues within 4Å:- Chain D: A.144, K.145, V.146, E.161
Ligand excluded by PLIPEDO.18: 4 residues within 4Å:- Chain D: T.10, S.12, P.141, E.143
Ligand excluded by PLIPEDO.28: 5 residues within 4Å:- Chain E: G.319, L.320, P.321, Q.552, F.555
Ligand excluded by PLIPEDO.29: 3 residues within 4Å:- Chain E: H.34, E.37
- Chain K: R.108
Ligand excluded by PLIPEDO.30: 6 residues within 4Å:- Chain E: G.214, Y.215, D.216, Y.217, T.567, K.577
Ligand excluded by PLIPEDO.31: 4 residues within 4Å:- Chain E: D.225, H.228, N.578, M.579
Ligand excluded by PLIPEDO.44: 3 residues within 4Å:- Chain F: G.319, Q.552, F.555
Ligand excluded by PLIPEDO.45: 4 residues within 4Å:- Chain F: Y.215, D.216, Y.217, K.577
Ligand excluded by PLIPEDO.46: 4 residues within 4Å:- Chain F: D.225, H.228, N.578, M.579
Ligand excluded by PLIPEDO.47: 3 residues within 4Å:- Chain F: H.34, E.37
- Chain L: R.108
Ligand excluded by PLIPEDO.54: 7 residues within 4Å:- Chain H: Q.37, K.39, K.45, R.61, F.62, E.81, D.82
Ligand excluded by PLIPEDO.55: 4 residues within 4Å:- Chain H: Q.6, P.101
- Chain J: A.14, D.17
Ligand excluded by PLIPEDO.56: 5 residues within 4Å:- Chain H: A.14, D.17
- Chain J: Q.6, S.9, P.101
Ligand excluded by PLIPEDO.59: 6 residues within 4Å:- Chain I: Y.59
- Chain J: P.95
- Chain L: S.80, T.81, F.82, K.83
Ligand excluded by PLIPEDO.60: 5 residues within 4Å:- Chain I: D.99, Y.106, D.108, Y.109
- Chain J: Q.55
Ligand excluded by PLIPEDO.61: 7 residues within 4Å:- Chain J: Q.37, K.39, K.45, R.61, F.62, E.81, D.82
Ligand excluded by PLIPEDO.62: 8 residues within 4Å:- Chain I: L.148, S.184, L.185, S.186
- Chain J: Q.161, S.177, S.178, T.179
Ligand excluded by PLIPEDO.64: 5 residues within 4Å:- Chain K: V.72, S.76, F.79
- Ligands: NAG-NAG.1, EDO.65
Ligand excluded by PLIPEDO.65: 6 residues within 4Å:- Chain K: F.47, N.48, S.78, F.79, W.141
- Ligands: EDO.64
Ligand excluded by PLIPEDO.66: 8 residues within 4Å:- Chain K: P.131, D.133, F.134, T.135, F.169, S.219, F.220, E.221
Ligand excluded by PLIPEDO.68: 6 residues within 4Å:- Chain F: H.34, E.35, D.38
- Chain L: Y.154, Q.198, S.199
Ligand excluded by PLIP- 22 x CL: CHLORIDE ION(Non-functional Binders)
CL.5: 1 residues within 4Å:- Chain A: N.169
Ligand excluded by PLIPCL.6: 3 residues within 4Å:- Chain A: T.72, D.73, T.74
Ligand excluded by PLIPCL.7: 4 residues within 4Å:- Chain A: E.46, W.47
- Chain B: T.97, F.98
Ligand excluded by PLIPCL.15: 2 residues within 4Å:- Chain C: N.59, R.102
Ligand excluded by PLIPCL.16: 3 residues within 4Å:- Chain C: E.108, S.109
- Chain L: R.51
Ligand excluded by PLIPCL.19: 2 residues within 4Å:- Chain D: Q.38, R.46
Ligand excluded by PLIPCL.20: 4 residues within 4Å:- Chain C: E.46, W.47
- Chain D: T.97, F.98
Ligand excluded by PLIPCL.32: 5 residues within 4Å:- Chain E: R.169, W.477, W.478, K.481, D.499
Ligand excluded by PLIPCL.33: 2 residues within 4Å:- Chain E: R.518, T.519
Ligand excluded by PLIPCL.34: 4 residues within 4Å:- Chain E: F.40, D.350, G.352, R.393
Ligand excluded by PLIPCL.35: 2 residues within 4Å:- Chain E: Y.515, R.518
Ligand excluded by PLIPCL.36: 2 residues within 4Å:- Chain E: E.375
- Ligands: ZN.21
Ligand excluded by PLIPCL.48: 4 residues within 4Å:- Chain F: R.169, W.477, W.478, D.499
Ligand excluded by PLIPCL.49: 2 residues within 4Å:- Chain F: D.350, R.393
Ligand excluded by PLIPCL.50: 2 residues within 4Å:- Chain F: W.271, R.273
Ligand excluded by PLIPCL.51: 3 residues within 4Å:- Chain F: E.375, E.402
- Ligands: ZN.37
Ligand excluded by PLIPCL.52: 3 residues within 4Å:- Chain F: E.232, N.580, R.582
Ligand excluded by PLIPCL.53: 2 residues within 4Å:- Chain G: T.40, T.41
Ligand excluded by PLIPCL.57: 1 residues within 4Å:- Chain H: S.157
Ligand excluded by PLIPCL.58: 1 residues within 4Å:- Chain H: S.28
Ligand excluded by PLIPCL.67: 4 residues within 4Å:- Chain E: H.34
- Chain K: R.108, E.111, N.122
Ligand excluded by PLIPCL.69: 2 residues within 4Å:- Chain L: R.60, F.169
Ligand excluded by PLIP- 2 x ZN: ZINC ION(Non-covalent)
ZN.21: 5 residues within 4Å:- Chain E: H.374, E.375, H.378, E.402
- Ligands: CL.36
3 PLIP interactions:3 interactions with chain E- Metal complexes: E:H.374, E:H.378, E:E.402
ZN.37: 5 residues within 4Å:- Chain F: H.374, E.375, H.378, E.402
- Ligands: CL.51
3 PLIP interactions:3 interactions with chain F- Metal complexes: F:H.374, F:H.378, F:E.402
- 13 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.22: 5 residues within 4Å:- Chain E: N.53, T.55, E.57, N.58, Q.340
5 PLIP interactions:5 interactions with chain E- Hydrogen bonds: E:N.53, E:T.55, E:E.57, E:N.58, E:Q.340
NAG.23: 3 residues within 4Å:- Chain E: K.26, N.90, V.93
2 PLIP interactions:2 interactions with chain E- Hydrogen bonds: E:K.26, E:N.90
NAG.24: 1 residues within 4Å:- Chain E: N.322
2 PLIP interactions:2 interactions with chain E- Hydrogen bonds: E:N.322
- Water bridges: E:N.322
NAG.25: 4 residues within 4Å:- Chain E: Q.81, Q.101, Q.102, N.103
1 PLIP interactions:1 interactions with chain E- Hydrogen bonds: E:Q.101
NAG.26: 2 residues within 4Å:- Chain E: S.420, N.546
4 PLIP interactions:4 interactions with chain E- Hydrogen bonds: E:S.420, E:S.420, E:S.420, E:N.546
NAG.27: 1 residues within 4Å:- Chain E: N.432
1 PLIP interactions:1 interactions with chain E- Hydrogen bonds: E:N.432
NAG.38: 5 residues within 4Å:- Chain F: N.53, T.55, E.57, N.58, Q.340
4 PLIP interactions:4 interactions with chain F- Hydrogen bonds: F:N.53, F:T.55, F:E.57, F:N.58
NAG.39: 3 residues within 4Å:- Chain F: K.26, N.90, V.93
2 PLIP interactions:2 interactions with chain F- Hydrogen bonds: F:K.26, F:N.90
NAG.40: 4 residues within 4Å:- Chain F: S.420, D.543, S.545, N.546
3 PLIP interactions:3 interactions with chain F- Hydrophobic interactions: F:S.420
- Hydrogen bonds: F:S.420, F:N.546
NAG.41: 1 residues within 4Å:- Chain F: N.322
1 PLIP interactions:1 interactions with chain F- Hydrogen bonds: F:N.322
NAG.42: 5 residues within 4Å:- Chain F: Q.81, Q.101, Q.102, N.103, N.194
4 PLIP interactions:4 interactions with chain F- Hydrogen bonds: F:Q.101, F:Q.101, F:N.103
- Water bridges: F:G.104
NAG.43: 1 residues within 4Å:- Chain F: N.432
No protein-ligand interaction detected (PLIP)NAG.63: 2 residues within 4Å:- Chain K: N.36, T.38
2 PLIP interactions:2 interactions with chain K- Hydrogen bonds: K:N.36, K:T.38
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Starr, T.N. et al., Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution. Science (2022)
- Release Date
- 2022-08-03
- Peptides
- S309 Fab Heavy Chain: AC
S309 Fab Light Chain: BD
Angiotensin-converting enzyme 2: EF
S304 Fab Heavy Chain: GI
S304 Fab Light Chain: HJ
Spike protein S1: KL - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AC
CB
BD
DE
EF
FG
HI
MH
LJ
NK
RL
S
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.70 Å
- Oligo State
- hetero-2-2-2-2-2-2-mer
- Ligands
- 2 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 30 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
- 22 x CL: CHLORIDE ION(Non-functional Binders)
- 2 x ZN: ZINC ION(Non-covalent)
- 13 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Starr, T.N. et al., Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution. Science (2022)
- Release Date
- 2022-08-03
- Peptides
- S309 Fab Heavy Chain: AC
S309 Fab Light Chain: BD
Angiotensin-converting enzyme 2: EF
S304 Fab Heavy Chain: GI
S304 Fab Light Chain: HJ
Spike protein S1: KL - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AC
CB
BD
DE
EF
FG
HI
MH
LJ
NK
RL
S